Clinical trial · Interventional
Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer
Phase II Study of Nimotuzumab and Concurrent Radiotherapy and Capecitabine for Inoperable Locally Advanced or Recurrent Gastric Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The prognosis of patients with inoperable locally advanced or residual/relapsed gastric cancer is rather poor. Concurrent capecitabine chemoradiotherapy is safe and recommended. Nimotuzumab, an anti-EGFR (epidermal growth factor receptor) monoclonal antibody, has shown its antitumor safety and efficiency in many phase I/II studies. Efficiency of combination of these treatment need to be further analyzed.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Concurrent Chemoradiotherapy | — | UNRESOLVED | — |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| nimotuzumab | Drug | Nimotuzumab | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- nimotuzumab
- description
- Combination of nimotuzumab and capecitabine concurrent chemoradiotherapy is received by patients.
- interventionNames
- Drug: nimotuzumab
Primary outcomes (1)
- measure
- progression-free survival
- timeFrame
- 1 year progression-free survival
- description
- progression-free survival: the time between tumor regression to progression
Secondary outcomes (2)
- measure
- overall responses
- timeFrame
- 1 month after treatment
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * 18-75 years old, male or female * Gastric cancer with measurable lesions, and the diameter is at least 1 cm * Karnofsky score: at least 70 * Estimated survival: at least 6 months * No prior target therapy or radiotherapy * No severe hypertension, cardiac disease, or diabetes mellitus * Normal blood routine and chemical tests * Signed consent Exclusion Criteria: * Other malignancies simultaneously except in situ cervix or non-melanoma skin cancer * Extensive distant metastases * Pregnancy or in lactation * Allergic to 5-Fluorouracil
References
Publications (0)
Data not yet available